The Third Time's The Scam.
Fooled me once, Shame on you; Fooled me twice, Shame on me; Fooled me a third time, And in came SEBI. When it comes to MNCs listed in India, premium valuations, competent managements, surging earnings and good corporate governance are certain hallmarks that define most of them. Exceptions, however, do dot the map, especially as far as that last criterion goes. And one exception just so happens to go by the name of AstraZeneca. All along, the Anglo – Swedish pharmaceutical giant has been more or less a dwarf in the Indian market, with only a small part of its vast drug portfolio being sold in the country. Seeing little purpose in being listed on the Indian markets and in the light of increasingly complex disclosure requirements mandated by SEBI, the company decided to delist in 2004. In its first delisting offer, or the reverse book – built offer, AstraZeneca offered a floor price of Rs. 825 / share, in order to go ahead with its delisting. Its Indian sha...